Eli Lilly And Co (NYSE:LLY) has reportedly reached a settlement agreement with a medi spa that sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, which contains tirzepatide. As part of the deal, Totality Medispa will pay Lilly a monetary payment and cease using Lilly’s branding to promote its products. In addition to the financial settlement, Totality Medispa is required to take corrective actions, including ensuring that any compounded tirzepatide products it obtains and distributes are produced in compliance with U.S. federal law. Related: Eli Lilly ‘On Its Way’ To $1 Trillion Market Cap, Analysts Say: It’s A ‘Have’ In A Sea Of ‘Have Nots’ In April, U.S. District Judge Roy ...